Day: October 14, 2025

At the end of September 2025, the net asset value (NAV) of UAB “Atsinaujinančios energetikos investicijos” (AEI) amounted to EUR 94,367,121, reflecting a decrease from EUR 96,476,602 reported at the end of June 2025. The share price declined to EUR 1.6088 compared to EUR 1.6447 as of June 2025. The pro forma internal rate of return (IRR) since inception decreased, reaching 0.84%, down from 1.50%, reported at the end of June 2025.   Solar projects In September 2025, AEI successfully completed the divestment of its 2.6 MW solar project in Lithuania UAB “Saulės Energijos Projektai“, as part of its ongoing divestment process. The construction of the 67.8 MW total capacity solar portfolio in Poland – PV Energy Projects sp. z o.o. – is approaching its final stages of development. As of the current reporting period, 49.8 MW of total capacity...

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 13, 2025 (GLOBE NEWSWIRE) — Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will deliver an oral presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held from October 22-26, 2025, in Boston, MA. Presentation details are as follows: Abstract title: Discovery of AN4035: A novel CEACAM5-targeting antibody drug conjugate (ADC) armed with a proprietary pan-RAS(ON) inhibitor payload, designed to broaden the therapeutic window Date and Time: Saturday, October 25, 2025; 11:45 AM – 12:15 PM ET Session Title: Spotlight on Proffered Papers 3: Novel Therapeutic Agents Location: Level 3,...

FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) — Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), today announced the following company operational update. Apollomics is a clinical-stage biotechnology company advancing innovative oncology therapies to transform the treatment landscape for patients with few or no options. With a pipeline of nine product candidates across 11 programs, including six in clinical development, the Company is focused on tackling some of the most challenging cancers, such as lung cancer, brain cancer, and other solid tumors. Apollomics’ strategic approach combines targeted therapies, immuno-oncology, and novel mechanisms of action designed to overcome resistance and deliver meaningful clinical outcomes. The Company is currently conducting a global Phase 2 trial of APL-101 (vebreltinib),...

WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) — Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease (“IBD”) and other immune-mediated diseases, today announced the pricing of its previously announced underwritten public offering of 14,864,865 shares of its common stock at a price to the public of $18.50 per share. The gross proceeds to the Company from this offering are expected to be approximately $275.0 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, the Company has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional...